
Denis Sasseville

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1966349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016. Journal of the American Academy of Dermatology, 2022, 86, 782-790.	1.2	16
2	Patch Testing to Carvone: North American Contact Dermatitis Group Experience, 2009 to 2018. Dermatitis, 2022, 33, 42-50.	1.6	5
3	Contact Dermatitis Associated With Hair Care Products: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2022, 33, 91-102.	1.6	12
4	Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018. Journal of the American Academy of Dermatology, 2022, 86, 818-826.	1.2	7
5	Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2022, 26, 33-49.	1.2	18
6	Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. Journal of the American Academy of Dermatology, 2022, 87, 1014-1023.	1.2	6
7	Patch Test Reactions Associated With Topical Medications: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001–2018). Dermatitis, 2022, 33, 144-154.	1.6	2
8	Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001–2016. Archives of Dermatological Research, 2022, 314, 857-867.	1.9	7
9	Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005–2018. Dermatitis, 2022, 33, 62-69.	1.6	3
10	Occupational Contact Dermatitis in Dental Personnel: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001 to 2018. Dermatitis, 2022, 33, 80-90.	1.6	6
11	Common Personal Care Products Contaminated With Benzene, a Known Human Carcinogen, Identified Recently. Journal of Cutaneous Medicine and Surgery, 2022, 26, 430-431.	1.2	1
12	Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada. Frontiers in Medicine, 2022, 9, 830254.	2.6	13
13	Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018. Journal of the American Academy of Dermatology, 2022, 87, 1024-1032.	1.2	6
14	Analysis of multiple basal cell carcinomas (BCCs) arising in one individual highlights genetic tumor heterogeneity and identifies novel driver mutations. Journal of Cell Communication and Signaling, 2022, 16, 633-635.	3.4	4
15	Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. Journal of the American Academy of Dermatology, 2022, 87, 1033-1041.	1.2	4
16	Lanolin Allergic Reactions: North American Contact Dermatitis Group Experience, 2001 to 2018. Dermatitis, 2022, Publish Ahead of Print, .	1.6	2
17	Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in Canada. Dermatology, 2022, 238, 1006-1017.	2.1	6
18	Patch testing with cobalt in children and adolescents: North American contact dermatitis group experience, 2001–2018. Contact Dermatitis, 2022, 87, 420-429.	1.4	2

#	Article	IF	CITATIONS
19	Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. Journal of the American Academy of Dermatology, 2021, 85, 1446-1455.	1.2	16
20	Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016. Journal of the American Academy of Dermatology, 2021, 84, 953-964.	1.2	16
21	Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 977-988.	1.2	6
22	Erythema multiformeâ€like eruption associated with plantâ€induced allergic contact dermatitis in a pediatric patient: A case report. Pediatric Dermatology, 2021, 38, 246-248.	0.9	2
23	Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 989-999.	1.2	8
24	Currently relevant p-phenylenediamine patch test reactions associated with hair dye and nonscalp anatomic areas: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 2001 to 2016. Journal of the American Academy of Dermatology, 2021, 84, e175-e177.	1.2	1
25	Patch Test Results and Outcome in Patients with Complications from Total Knee Arthroplasty: A Consecutive Case Series. Journal of Knee Surgery, 2021, 34, 233-241.	1.6	9
26	Patch Testing With a New Composition of the Mercapto Mix—A Multicenter Study from the International Contact Dermatitis Research Group. Dermatitis, 2021, 32, 160-163.	1.6	0
27	Patch Testing With Methylchloroisothiazolinone/Methylisothiazolinone Using a New Diagnostic Mix—A Multicenter Study From the International Contact Dermatitis Research Group. Dermatitis, 2021, 32, 220-224.	1.6	1
28	Patch Testing With Carmine 2.5% in Petrolatum by the North American Contact Dermatitis Group, 2011–2012. Dermatitis, 2021, 32, 94-100.	1.6	2
29	Incidence and Mortality of Prostate Cancer in Canada during 1992–2010. Current Oncology, 2021, 28, 978-990.	2.2	9
30	North American Contact Dermatitis Group Patch Test Results: 2017–2018. Dermatitis, 2021, 32, 111-123.	1.6	78
31	Epidemiologic trends and geographic distribution of patients with gallbladder and extrahepatic biliary tract cancers in Canada. Hpb, 2021, 23, 1541-1549.	0.3	4
32	Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001–2016. Contact Dermatitis, 2021, 85, 46-57.	1.4	6
33	Prevalence and Trend of Allergen Sensitization in Adults and Children with Atopic Dermatitis Referred for Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2853-2866.e14.	3.8	9
34	Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000–2016*. British Journal of Dermatology, 2021, 185, 185-194.	1.5	5
35	Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994–2018. Dermatitis, 2021, 32, 256-266.	1.6	2
36	Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018. Contact Dermatitis, 2021, 85, 285-296.	1.4	7

#	Article	IF	CITATIONS
37	Contact dermatitis in music professionals referred for patch testing: North <scp>American</scp> Contact Dermatitis Group data, 1996–2018. Contact Dermatitis, 2021, 85, 359-362.	1.4	ο
38	Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016. Journal of the American Academy of Dermatology, 2021, 84, 965-976.	1.2	17
39	Geographic and Socioeconomic Disparity of Gastric Cancer Patients in Canada. Current Oncology, 2021, 28, 2052-2064.	2.2	7
40	Interâ€ f ater variability in patch test readings and final interpretation using storeâ€forward teledermatology. Contact Dermatitis, 2021, 85, 274-284.	1.4	6
41	The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets. Life Science Alliance, 2021, 4, e202000651.	2.8	12
42	Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: <scp>N</scp> orth <scp>A</scp> merican <scp>C</scp> ontact <scp>D</scp> ermatitis <scp>G</scp> roup data, 2001â€2016. Contact Dermatitis, 2021, 85, 435-445.	1.4	3
43	Contact Dermatitis Associated With Musical Instruments. Dermatitis, 2021, Publish Ahead of Print, e156-e158.	1.6	Ο
44	Contact Allergy in Canada Versus United States. Dermatitis, 2021, Publish Ahead of Print, 421-429.	1.6	1
45	Benzene, a Known Human Carcinogen, Detected in Suncare Products. Journal of Cutaneous Medicine and Surgery, 2021, 25, 650-651.	1.2	5
46	Patients with patch test reactions associated with eye care products: Retrospective analysis of <scp>N</scp> orth <scp>A</scp> merican contact dermatitis group data, <scp>2001</scp> â€ <scp>2018</scp> . Contact Dermatitis, 2021, 85, 712-715.	1.4	2
47	Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
48	Patch Testing to Ethylhexylglycerin. Dermatitis, 2021, Publish Ahead of Print, .	1.6	0
49	Patch Testing With Tocopherol and Tocopherol Acetate: The North American Contact Dermatitis Group Experience, 2001 to 2016. Dermatitis, 2021, 32, 308-318.	1.6	3
50	Fragrance- and Botanical-Related Allergy and Associated Concomitant Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 2007–2016. Dermatitis, 2021, 32, 42-52.	1.6	15
51	Acetophenone Azine. Dermatitis, 2021, 32, 5-9.	1.6	8
52	Comparison of Different Metal Salts: Nickel Sulfate 2.5% Versus 5% and Palladium Chloride Versus Sodium Tetrachloropalladate. Dermatitis, 2021, 32, e44-e45.	1.6	0
53	Positive Patch Test Reactions to Carba Mix and Thiuram Mix: The North American Contact Dermatitis Group Experience (1994–2016). Dermatitis, 2021, 32, 173-184.	1.6	7
54	Patch Testing of Mercaptobenzothiazole and Mercapto Mix: The North American Contact Dermatitis Group Experience, 1994–2016. Dermatitis, 2021, 32, 232-244.	1.6	2

#	Article	IF	CITATIONS
55	Patch Test Reactions Associated With Nontopical Medications: A Retrospective Analysis of North American Contact Dermatitis Group Data, 2001–2018. Dermatitis, 2021, 32, e127-e129.	1.6	1
56	Incidence trends of conjunctival malignant melanoma in Canada. British Journal of Ophthalmology, 2020, 104, 23-25.	3.9	29
57	Allergic reactions to tattoos: Retrospective analysis of North American Contact Dermatitis Group data, 2001-2016. Journal of the American Academy of Dermatology, 2020, 82, e61-e62.	1.2	6
58	Epidemiologic trends and geographic distribution of esophageal cancer in Canada: A national populationâ€based study. Cancer Medicine, 2020, 9, 401-417.	2.8	20
59	Incidence of acute myeloid leukemia: A regional analysis of Canada. Cancer, 2020, 126, 1356-1361.	4.1	3
60	Penile Invasive Squamous Cell Carcinoma: Analysis of Incidence, Mortality Trends, and Geographic Distribution in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 124-128.	1.2	15
61	Facial Dermatitis in Male Patients Referred for Patch Testing. JAMA Dermatology, 2020, 156, 79.	4.1	16
62	Evaluation of Patch Test Findings in Patients With Anogenital Dermatitis. JAMA Dermatology, 2020, 156, 85.	4.1	11
63	Cutaneous polyarteritis nodosa and concurrent pseudoxanthoma elasticum–like phenotype: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2095311.	0.3	0
64	Contact Allergy to Fragrance Mix II and Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde: A Retrospective Study by International Contact Dermatitis Research Group. Dermatitis, 2020, 31, 268-271.	1.6	6
65	16110 In silico analyses of the tumor microenvironment in basal cell carcinoma highlight the importance of TH2 cytokine profile, tumor-associated macrophages, and acquisition of mesenchymal stem cell-like phenotype in advanced and treatment-resistant tumors. Journal of the American Academy of Dermatology, 2020, 83, AB54.	1.2	0
66	Hypopigmented Mycosis Fungoides: Loss of Pigmentation Reflects Antitumor Immune Response in Young Patients. Cancers, 2020, 12, 2007.	3.7	12
67	Revised Baseline Series of the International Contact Research Group. Dermatitis, 2020, 31, e5-e7.	1.6	12
68	Investigating Epidemiologic Trends and the Geographic Distribution of Patients with Anal Squamous Cell Carcinoma throughout Canada. Current Oncology, 2020, 27, 294-306.	2.2	6
69	Allergic contact dermatitis from acetophenone azine in a Canadian child. Contact Dermatitis, 2020, 83, 41-42.	1.4	6
70	Epidemiology of Adult and Pediatric Burkitt Lymphoma in Canada: Sequelae of the HIV Epidemic. Current Oncology, 2020, 27, 83-89.	2.2	8
71	Contact Dermatitis Associated With Nail Care Products: Retrospective Analysis of North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2020, 31, 191-201.	1.6	19
72	Epidemiology of ophthalmic lymphoma in Canada during 1992–2010. British Journal of Ophthalmology, 2020, 104, 1176-1180.	3.9	10

#	Article	IF	CITATIONS
73	In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas. Journal of Cell Communication and Signaling, 2020, 14, 245-254.	3.4	18
74	Epidemiology and Patient Distribution of Oral Cavity and Oropharyngeal SCC in Canada. Journal of Cutaneous Medicine and Surgery, 2020, 24, 340-349.	1.2	19
75	Severe allergic contact blepharitis from propolis. Contact Dermatitis, 2020, 82, 399-400.	1.4	2
76	Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib. JAAD Case Reports, 2020, 6, 172-175.	0.8	4
77	Epidemiology of invasive ocular surface squamous neoplasia in Canada during 1992–2010. British Journal of Ophthalmology, 2020, 104, 1368-1372.	3.9	17
78	Poor prognosis of drugâ€induced and acute graftâ€versusâ€host diseaseâ€induced epidermal necrolysis in bone marrow/stem cell transplant recipients: a retrospective case series. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e506-e510.	2.4	0
79	Patch Testing to Diphenylguanidine by the North American Contact Dermatitis Group (2013–2016). Dermatitis, 2020, 31, 350-358.	1.6	2
80	Expanding Patch Testing Beyond the Baseline Series: Usefulness of Customized Antimicrobials, Vehicles, and Cosmetics Series. Dermatitis, 2020, 31, 367-372.	1.6	6
81	The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL). Frontiers in Oncology, 2019, 9, 429.	2.8	16
82	Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada. Cancer, 2019, 125, 3953-3959.	4.1	13
83	Incidence and Mortality Trends and Geographic Patterns of Follicular Lymphoma in Canada. Current Oncology, 2019, 26, 473-481.	2.2	18
84	Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada. Breast Cancer Research and Treatment, 2019, 178, 683-691.	2.5	25
85	Parabens. Dermatitis, 2019, 30, 3-31.	1.6	105
86	Incidence, Mortality, and Spatiotemporal Distribution of Cutaneous Malignant Melanoma Cases Across Canada. Journal of Cutaneous Medicine and Surgery, 2019, 23, 394-412.	1.2	35
87	Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). Frontiers in Oncology, 2019, 9, 300.	2.8	47
88	Patients with negative patch tests: Retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016. Journal of the American Academy of Dermatology, 2019, 80, 1618-1629.	1.2	11
89	Time-Saving Comparison of Wound Measurement Between the Ruler Method and the Swift Skin and Wound App. Journal of Cutaneous Medicine and Surgery, 2019, 23, 226-228.	1.2	18
90	Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. British Journal of Ophthalmology, 2019, 103, bjophthalmol-2018-312966.	3.9	38

#	Article	IF	CITATIONS
91	Trends in incidence of cutaneous malignant melanoma in Canada: 1992-2010 versus 2011-2015. Journal of the American Academy of Dermatology, 2019, 80, 1157-1159.	1.2	31
92	Safety equipment: When protection becomes a problem. Contact Dermatitis, 2019, 81, 130-132.	1.4	20
93	Prevalence of Human T Cell Lymphotropic Virus 1 Infection in Canada. Current Oncology, 2019, 26, 3-5.	2.2	14
94	Filaggrin gene lossâ€ofâ€function mutations constitute a factor in patients with multiple contact allergies. Contact Dermatitis, 2019, 80, 354-358.	1.4	15
95	Multiple myeloma epidemiology and patient geographic distribution in Canada: A population study. Cancer, 2019, 125, 2435-2444.	4.1	32
96	Epidemiology of nickel sensitivity: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data 1994-2014. Journal of the American Academy of Dermatology, 2019, 80, 701-713.	1.2	25
97	Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario. Cancer, 2019, 125, 1886-1897.	4.1	36
98	Occupationally Related Nickel Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 1998–2016. Dermatitis, 2019, 30, 306-313.	1.6	15
99	Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study. Journal of the American Academy of Dermatology, 2019, 80, 448-459.	1.2	55
100	Retinoblastoma Incidence Trends in Canada: A National Comprehensive Population-Based Study. Journal of Pediatric Ophthalmology and Strabismus, 2019, 56, 124-130.	0.7	33
101	Occupational allergic contact dermatitis caused by hexahydrophthalic acid diglycidyl ester and anhydride epoxy hardeners. Contact Dermatitis, 2018, 79, 39-40.	1.4	2
102	Epidemiology of pediatric nickel sensitivity: Retrospective review of North American Contact Dermatitis Group (NACDG) data 1994-2014. Journal of the American Academy of Dermatology, 2018, 79, 664-671.	1.2	34
103	Contact Dermatitis Associated With Skin Cleansers: Retrospective Analysis of North American Contact Dermatitis Group Data 2000–2014. Dermatitis, 2018, 29, 32-42.	1.6	19
104	Distribution and Clustering of Cutaneous T-Cell Lymphoma (CTCL) Cases in Canada During 1992 to 2010. Journal of Cutaneous Medicine and Surgery, 2018, 22, 154-165.	1.2	42
105	Insights into the Pathophysiology of Hypertrophic Scars and Keloids: How Do They Differ?. Advances in Skin and Wound Care, 2018, 31, 582-595.	1.0	72
106	Occupational Contact Dermatitis in the Canadian Aircraft Industry. Dermatitis, 2018, 29, 139-150.	1.6	6
107	North American Contact Dermatitis Group Patch Test Results: 2015–2016. Dermatitis, 2018, 29, 297-309.	1.6	230
108	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncolmmunology, 2018, 7, e1467856.	4.6	24

#	Article	IF	CITATIONS
109	A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL). Oncotarget, 2018, 9, 37647-37661.	1.8	23
110	Comprehensive analysis of cutaneous Tâ€cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer, 2017, 123, 3550-3567.	4.1	70
111	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncolmmunology, 2017, 6, e1306618.	4.6	78
112	Simultaneous contact dermatitis caused by Asteraceae and <i>Verbascum thapsus</i> . Contact Dermatitis, 2017, 76, 316-318.	1.4	4
113	Wet Wipe Allergens: Retrospective Analysis From the North American Contact Dermatitis Group 2011–2014. Dermatitis, 2017, 28, 64-69.	1.6	21
114	Alkyl Glucosides: 2017 "Allergen of the Year― Dermatitis, 2017, 28, 296-296.	1.6	20
115	Positive Patch-Test Reactions to Essential Oils in Consecutive Patients From North America and Central Europe. Dermatitis, 2017, 28, 246-252.	1.6	35
116	Patch Test Reactions to Corticosteroids: Retrospective Analysis From the North American Contact Dermatitis Group 2007–2014. Dermatitis, 2017, 28, 58-63.	1.6	26
117	Evaluating Comorbidities, Natural History, and Predictors of Early Resolution in a Cohort of Children With Chronic Urticaria. JAMA Dermatology, 2017, 153, 1236.	4.1	61
118	Malignant T cells activate endothelial cells via IL-17 F. Blood Cancer Journal, 2017, 7, e586-e586.	6.2	12
119	Occupational Contact Dermatitis in Mechanics and Repairers Referred for Patch Testing: Retrospective Analysis From the North American Contact Dermatitis Group 1998–2014. Dermatitis, 2017, 28, 47-57.	1.6	17
120	Piercing and Metal Sensitivity: Extended Analysis of the North American Contact Dermatitis Group Data, 2007–2014. Dermatitis, 2017, 28, 333-341.	1.6	27
121	North American Contact Dermatitis Group Patch Test Results 2013–2014. Dermatitis, 2017, 28, 33-46.	1.6	171
122	Allergic contact dermatitis caused by pentaerythrityl tetracaprylate/tetracaprate. Contact Dermatitis, 2017, 77, 58-59.	1.4	3
123	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. Frontiers in Medicine, 2017, 4, 153.	2.6	16
124	Point-of-care wound visioning technology: Reproducibility and accuracy of a wound measurement app. PLoS ONE, 2017, 12, e0183139.	2.5	53
125	Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome <i>vs. HTLV-1+</i> leukemic cell lines. Oncotarget, 2017, 8, 95981-95998.	1.8	44
126	Contact Allergy to Polymyxin B Among Patients Referred for Patch Testing. Dermatitis, 2016, 27, 119-122.	1.6	11

#	Article	IF	CITATIONS
127	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016, 127, 1287-1296.	1.4	86
128	Systemic contact dermatitis caused by inhaled cashew oil smoke. Contact Dermatitis, 2016, 75, 248-250.	1.4	5
129	Patch Testing for Evaluation of Hypersensitivity to Implanted Metal Devices: A Perspective From the American Contact Dermatitis Society. Dermatitis, 2016, 27, 241-247.	1.6	58
130	The Association of Race/Ethnicity and Patch Test Results: North American Contact Dermatitis Group, 1998–2006. Dermatitis, 2016, 27, 288-292.	1.6	34
131	The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2016, 136, 866-869.	0.7	4
132	Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. Oncolmmunology, 2016, 5, e1175799.	4.6	36
133	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget, 2016, 7, 45730-45744.	1.8	45
134	Demographic patterns of cutaneous T ell lymphoma incidence in Texas based on two different cancer registries. Cancer Medicine, 2015, 4, 1440-1447.	2.8	44
135	Pachyonychia Congenita (K16) with Unusual Features and Good Response to Acitretin. Case Reports in Dermatology, 2015, 7, 220-226.	0.8	8
136	"Parabenoia―Debunked, or "Who's Afraid of Parabens?― Dermatitis, 2015, 26, 254-259.	1.6	33
137	Cutaneous Delayed-Type Hypersensitivity to Surfactants. Dermatitis, 2015, 26, 268-270.	1.6	7
138	Leitlinie für die Diagnose, Präention und Behandlung des Handekzems – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2015, 13, 77-85.	0.8	4
139	Multicenter Patch Testing With a Resol Resin Based on Phenol and Formaldehyde Within the International Contact Dermatitis Research Group. Dermatitis, 2015, 26, 230-234.	1.6	16
140	Patch Testing To a Textile Dye Mix by the International Contact Dermatitis Research Group. Dermatitis, 2015, 26, 170-176.	1.6	24
141	Pustular flagellate dermatitis after consumption of shiitake mushrooms. JAAD Case Reports, 2015, 1, 117-119.	0.8	17
142	Eruptive Disseminated Pyogenic Granulomas following Lightning Injury. Dermatology, 2015, 230, 199-203.	2.1	7
143	Identification of geographic clustering and regions spared by cutaneous Tâ€cell lymphoma in Texas using 2 distinct cancer registries. Cancer, 2015, 121, 1993-2003.	4.1	45
144	The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clinical Cancer Research, 2015, 21, 2820-2829.	7.0	76

ARTICLE IF CITATIONS North American Contact Dermatitis Group Patch Test Results. Dermatitis, 2015, 26, 49-59. 145 Scurvy. JAMA Dermatology, 2015, 151, 431. 146 4.1 2 Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T 1.8 cells from cutaneous T cell lymphoma (CTCL) patients. Oncotarget, 2015, 6, 14374-14384. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous 148 1.8 78 T-Cell lymphoma. Oncotarget, 2015, 6, 20555-20569. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle, 2014, 13, 149 2.6 1306-1312. 150 Pyoderma gangrenosum triggered by red tattoo dye. Cmaj, 2014, 186, 935-935. 2.0 15 Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle, 2014, 13, 3331-3335. 2.6 Occupational allergic contact dermatitis caused by omeprazole in a horse breeder. Contact 152 1.4 14 Dermatitis, 2014, 71, 377-378. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell 2.6 lines. Cell Cycle, 2014, 13, 2975-2982. 154 Allergic Contact Dermatitis From Ethylhexylglycerin in Sunscreens. Dermatitis, 2014, 25, 42-43. 1.6 21 Patch Testing in Children From 2005 to 2012. Dermatitis, 2014, 25, 345-355. 96 1.6 156 Body Piercing and Metal Allergic Contact Sensitivity. Dermatitis, 2014, 25, 255-264. 1.6 22 Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell 4.6 38 lymphoma. Oncolmmunology, 2014, 3, e970025. Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients. Clinical Cancer 158 7.0 40 Research, 2014, 20, 3799-3808. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in 1.8 mycosis fungoides and correlates with poor prognosis. Oncotarget, 2014, 5, 4418-4425. Evaluation of Varicella Zoster Virus Infection Morbidity and Mortality in Pancreas and 160 0.6 13 Kidney-Pancreas Transplant Recipients. Transplantation Proceedings, 2013, 45, 701-704. Evaluation of Herpes Simplex Virus Infection Morbidity and Mortality in Pancreas and Kidney-Pancreas 0.6 Transplant Recipients. Transplantation Proceedings, 2013, 45, 3343-3347. Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage 162 1.320 cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 653-654.

#	Article	IF	CITATIONS
163	Positive Patch Test Reactions to Carba Mix and Iodopropynyl Butylcarbamate. Dermatitis, 2013, 24, 241-245.	1.6	9
164	North American Contact Dermatitis Group Patch Test Results. Dermatitis, 2013, 24, 50-59.	1.6	193
165	Patch Test Reactions Associated With Sunscreen Products and the Importance of Testing to an Expanded Series. Dermatitis, 2013, 24, 176-182.	1.6	43
166	Concomitant Patch Test Reactions to Mercapto Mix and Mercaptobenzothiazole. Dermatitis, 2013, 24, 321-327.	1.6	4
167	Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155. Cell Cycle, 2013, 12, 2172-2172.	2.6	20
168	North American Contact Dermatitis Group Patch Test Results for 2007–2008. Dermatitis, 2013, 24, 10-21.	1.6	121
169	Thiurams in shoe contact dermatitis – a case series. Contact Dermatitis, 2013, 68, 185-187.	1.4	6
170	Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood, 2013, 122, 943-950.	1.4	78
171	Acrylates. Dermatitis, 2012, 23, 3-5.	1.6	14
172	Positive patch test reactions in older individuals: Retrospective analysis from the North American Contact Dermatitis Group, 1994-2008. Journal of the American Academy of Dermatology, 2012, 66, 229-240.	1.2	62
173	The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression. Experimental Dermatology, 2012, 21, 964-966.	2.9	21
174	Acrylates in Contact Dermatitis. Dermatitis, 2012, 23, 6-16.	1.6	75
175	Occupational contact allergens: Are they also associated with occupational asthma?. American Journal of Industrial Medicine, 2012, 55, 353-360.	2.1	32
176	Occupational contact urticaria caused by polyvinylchloride gloves. Contact Dermatitis, 2012, 66, 49-50.	1.4	3
177	Contact dermatitis from topical antibiotics. European Journal of Dermatology, 2011, 21, 311-322.	0.6	3
178	Occupational allergic contact dermatitis caused by morphine. Contact Dermatitis, 2011, 64, 166-168.	1.4	12
179	Allergic contact dermatitis caused by glycyrrhetinic acid and castor oil. Contact Dermatitis, 2011, 64, 168-169.	1.4	11
180	Multiple contact allergies to benzophenones. Contact Dermatitis, 2011, 65, 179-180.	1.4	11

#	Article	IF	CITATIONS
181	CD109 release from the cell surface in human keratinocytes regulates TGF-β receptor expression, TGF-β signalling and STAT3 activation: relevance to psoriasis. Experimental Dermatology, 2011, 20, 627-632.	2.9	53
182	Revised minimal baseline series of the International Contact Dermatitis Research Group: evidence-based approach. Dermatitis, 2011, 22, 121-2.	1.6	2
183	Importance of CD109 and Transforming Growth Factor-β Signaling in Psoriasis. Psoriasis Forum, 2010, 16a, 16-19.	0.1	Ο
184	Positivity Ratio and Reaction Index: Patch-Test Quality-Control Metrics Applied to the North American Contact Dermatitis Group Database. Dermatitis, 2010, 21, 91-97.	1.6	51
185	Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma. Clinical Cancer Research, 2010, 16, 2106-2114.	7.0	76
186	Canadian Hand Dermatitis Management Guidelines. Journal of Cutaneous Medicine and Surgery, 2010, 14, 267-284.	1.2	44
187	Neomycin. Dermatitis, 2010, 21, 3-7.	1.6	4
188	Allergen content of patient problem and nonproblem gloves: relationship to allergen-specific patch-test findings. Dermatitis, 2010, 21, 77-83.	1.6	3
189	Positivity ratio and reaction index: patch-test quality-control metrics applied to the north american contact dermatitis group database. Dermatitis, 2010, 21, 91-7.	1.6	3
190	Emergent and unusual allergens in cosmetics. Dermatitis, 2010, 21, 127-37.	1.6	2
191	Dermatitis from plants ofÂtheÂnew world. European Journal of Dermatology, 2009, 19, 423-430.	0.6	4
192	Allergic contact cheilitis from D & amp; C Yellow 11. Contact Dermatitis, 2009, 60, 294-295.	1.4	11
193	Allergic contact dermatitis from occupational exposure to dibutyl maleate. Contact Dermatitis, 2009, 60, 298-300.	1.4	3
194	Occupational allergic contact dermatitis from sodium metabisulfite. Contact Dermatitis, 2009, 61, 244-245.	1.4	18
195	Allergic contact dermatitis from tincture of benzoin with multiple concomitant reactions. Contact Dermatitis, 2009, 61, 358-360.	1.4	16
196	Allergic patch test reactions associated with cosmetics: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2004. Journal of the American Academy of Dermatology, 2009, 60, 23-38.	1.2	87
197	Clinical Patterns of Phytodermatitis. Dermatologic Clinics, 2009, 27, 299-308.	1.7	42
198	Positive Patch-Test Reactions to Propylene Glycol: A Retrospective Cross-Sectional Analysis from the North American Contact Dermatitis Group, 1996 to 2006. Dermatitis, 2009, 20, 14-20.	1.6	54

#	Article	IF	CITATIONS
199	Occupational Contact Dermatitis. Allergy, Asthma and Clinical Immunology, 2008, 4, 59-65.	2.0	67
200	The value of patch testing patients with a scattered generalized distribution of dermatitis: Retrospective cross-sectional analyses of North American Contact Dermatitis Group data, 2001 to 2004. Journal of the American Academy of Dermatology, 2008, 59, 426-431.	1.2	42
201	Contact Allergy in Children Referred for Patch Testing. Archives of Dermatology, 2008, 144, 1329-36.	1.4	140
202	Psychopharmacology in Psychodermatology. Journal of Cutaneous Medicine and Surgery, 2008, 12, 255-267.	1.2	5
203	Anogenital Dermatitis in Patients Referred for Patch Testing. Archives of Dermatology, 2008, 144, 749-55.	1.4	53
204	Patch-test reactions to topical anesthetics: retrospective analysis of cross-sectional data, 2001 to 2004. Dermatitis, 2008, 19, 81-5.	1.6	5
205	North American Contact Dermatitis Group patch-test results, 2003-2004 study period. Dermatitis, 2008, 19, 129-36.	1.6	12
206	Positive patch-test reactions to mixed dialkyl thioureas: cross-sectional data from the North American Contact Dermatitis Group, 1994 to 2004. Dermatitis, 2008, 19, 190-201.	1.6	2
207	Contact dermatitis associated with food: retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 2001-2004. Dermatitis, 2008, 19, 252-60.	1.6	9
208	Common Contact Allergens Associated with Eyelid Dermatitis: Data from the North American Contact Dermatitis Group 2003-2004 Study Period. Dermatitis, 2007, 18, 78-81.	1.6	51
209	Cross-Reactions between Xanthates and Rubber Additives. Dermatitis, 2007, 18, 150-154.	1.6	6
210	Psoriasis of the nail: Anatomy, pathology, clinicalÂpresentation, and a review of the literature on therapy. Journal of the American Academy of Dermatology, 2007, 57, 1-27.	1.2	383
211	Contact dermatitis of the hands: Cross-sectional analyses of North American Contact Dermatitis Group Data, 1994-2004. Journal of the American Academy of Dermatology, 2007, 57, 301-314.	1.2	91
212	Allergic contact dermatitis to idebenone used as an antioxidant in an anti-wrinkle cream. Contact Dermatitis, 2007, 56, 117-118.	1.4	20
213	Erythema annulare centrifugum secondary to treatment with finasteride. Journal of Drugs in Dermatology, 2007, 6, 460-3.	0.8	8
214	Delayed-Type Hypersensitivity to Fragrance Materials in a Select North American Population. Dermatitis, 2006, 17, 23-28.	1.6	33
215	The Relationship of Vehicle and Concentration of Imidazolidinylurea, with Attention to Formaldehyde Allergy Status. Dermatitis, 2006, 17, 48-49.	1.6	6
216	Dermatologic Surgery Practice and Skin Cancer Treatment in Canada: Results of a National Survey. Dermatologic Surgery, 2006, 31, 27-32.	0.8	2

#	Article	IF	CITATIONS
217	Dermatologic Treatment during Pregnancy: Practical Overview. Journal of Cutaneous Medicine and Surgery, 2006, 10, 183-192.	1.2	9
218	Treatment of Mycosis Fungoides: Overview. Journal of Cutaneous Medicine and Surgery, 2006, 10, 228-233.	1.2	10
219	OCCUPATIONAL ALLERGIC CONTACT DERMATITIS FROM TRIPHENYL PHOSPHITE. Dermatitis, 2005, 16, 95.	1.6	Ο
220	Allergic contact dermatitis from triphenyl phosphite. Contact Dermatitis, 2005, 52, 163-164.	1.4	6
221	Allergic contact dermatitis from triethanolamine polypeptide oleate condensate in eardrops and shampoo. Contact Dermatitis, 2005, 52, 233-233.	1.4	5
222	Hypersensitivity to preservatives. Dermatologic Therapy, 2004, 17, 251-263.	1.7	93
223	Contact allergy to 1-bromo-3-chloro-5, 5-dimethylhydantoin in spa water. Contact Dermatitis, 2004, 50, 323-324.	1.4	7
224	Allergic Contact Dermatitis from Cocamidopropyl Betaine, Cocamidoamine, 3-(Dimethylamino)propylamine, and Oleamidopropyl Dimethylamine: Co-reactions or Cross-Reactions?. Dermatitis, 2004, 15, 146.	1.6	24
225	Allergic Contact Dermatitis from Isocyanates among Sculptors. Dermatitis, 2004, 15, 150.	1.6	21
226	North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis, 2004, 15, 176-83.	1.6	176
227	Occupational allergic contact dermatitis from 1,2-benzisothiazolin-3-one without cross-sensitization to other isothiazolinones. Contact Dermatitis, 2003, 48, 230-231.	1.4	12
228	Occupational Allergic Contact Dermatitis from Xanthates and Carbamates in Mining Processes. Dermatitis, 2003, 14, 166.	1.6	2
229	Bus Pass Dermatitis. Dermatitis, 2002, 13, 146-147.	1.6	0
230	Sensitization to Paraâ€Phenylenediamine from a Streetside Temporary Tattoo. Pediatric Dermatology, 2002, 19, 498-502.	0.9	115
231	Cross-reactivity among epoxy acrylates and bisphenol F epoxy resins in patients with bisphenol A epoxy resin sensitivity. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2002, 13, 108-15.	0.4	9
232	Bus pass dermatitis. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2002, 13, 146-7.	0.4	2
233	Kanerva L, Elsner P, Wahlberg JE, Maibach HI: Handbook of Occupational Dermatology, Springer Verlag, Berlin, Heidelberg, New York, 2000. ISBN 3-540-64046-0, 1300 pages. 194 figures (70 in color). 350 tables, \$295. Dermatitis, 2001, 12, 45-46.	1.6	0
234	Occupational Contact Dermatitis to Textile Dyes in Airline Personnel. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2001, 12, 208-210.	0.4	3

#	Article	IF	CITATIONS
235	Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing. Contact Dermatitis, 2001, 45, 232-233.	1.4	1
236	Allergic Contact Dermatitis to Epoxy Resin in Microscopy Immersion Oil: Cases From Canada. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2000, 11, 99-103.	0.4	13
237	Allergic contact dermatitis to tea tree oil with erythema multiforme–like ID reaction. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2000, 11, 238-242.	0.4	57
238	Pseudoporphyria Induced by Propionic Acid Derivatives. Journal of Cutaneous Medicine and Surgery, 1999, 3, 162-166.	1.2	28
239	Allergic contact dermatitis from chlorinated swimming pool water. Contact Dermatitis, 1999, 41, 347-348.	1.4	27
240	Interferon-Induced Cutaneous Necrosis. Journal of Cutaneous Medicine and Surgery, 1999, 3, 320-323.	1.2	15
241	Phytodermatitis. Journal of Cutaneous Medicine and Surgery, 1999, 3, 263-279.	1.2	18
242	Contact urticaria from epoxy resin and reactive diluents. Contact Dermatitis, 1998, 38, 57-58.	1.4	27
243	Narrow spectrum of cross-sensitization with pyridine derivatives. Contact Dermatitis, 1998, 38, 212-214.	1.4	3
244	Occupational contact dermatitis from ethylenediamine in a wire-drawing lubricant. Contact Dermatitis, 1997, 36, 228-228.	1.4	12
245	Allergic contact dermatitis from hydrocolloid dressings. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 1997, 8, 236-8.	0.4	20
246	Contact sensitization to pyridine derivatives. Contact Dermatitis, 1996, 35, 100-125.	1.4	22
247	Allergic contact dermatitis fromRhus toxicodendronin a phytotherapeutic preparation. Contact Dermatitis, 1995, 32, 182-183.	1.4	14
248	Generalized contact dermatitis from acetarsone. Contact Dermatitis, 1995, 33, 431-432.	1.4	6
249	Rothmund-Thomson syndrome with osteosarcoma. Journal of the American Academy of Dermatology, 1993, 28, 301-305.	1.2	42
250	Dermatoses of Pregnancy. International Journal of Dermatology, 1981, 20, 223-248.	1.0	73